title: The impact of neoadjuvant chemotherapy on patients with locally advanced breast cancer in a Nigerian semiurban teaching hospital: a single-center descriptive study.
abstract: BACKGROUND
  There is a paucity of data on the response of breast cancer to neoadjuvant c in low-resources developing African countries such as Nigeria. We therefore decided to study the impact of neoadjuvant chemotherapy on breast cancer patients in Nigeria in the light of constrained resources.
  
  
  METHODS
  This was a single-center retrospective descriptive study. Sixty-two patients with locally advanced breast cancer treated with neoadjuvant chemotherapy in the last 24 years in Obafemi Awolowo University Teaching Hospital Complex (OAUTHC), Ile-Ife, Nigeria, constituted the study population. The outcome measures were clinical tumor response, disease-free survival, overall survival, and chemotherapy toxicity profile.
  
  
  RESULTS
  Patients ranged in age from 30 to 85 years (mean = 49.1 +/- SD 12.7 years) and included one male. After three cycles of chemotherapy, complete clinical response was observed in 4 patients (6.5%), partial clinical response in 28 patients (45.2%), no clinically measurable response in 24 patients (38.7%), and progressive disease in 6 patients (9.7%). Forty-one patients completed six cycles, of which 9 patients (22.0%) had complete clinical response and 12 patients (29.3%) had partial clinical response. Four of 30 patients (13.3%) with tumor size of 6-10 cm had complete clinical response, while no patient with a tumor bigger than 10 cm had complete clinical response. Of the 62 patients, 42 were followed up for more than 1 year. The 1-, 2-, and 5-year survival rates of this cohort were 66.7, 42.9, and 11.9%, respectively The median follow-up period was 9 months and the disease-free survival and overall survival rates at median follow-up period were 45 and 37%, respectively.
  
  
  CONCLUSIONS
  There was a poor overall clinical response rate to neoadjuvant chemotherapy in the Black population studied. Late presentation with large tumor mass may be accountable for this.
authors.affiliation: Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile Ife, 220005, Osun State, Nigeria. arowolodoctor1@yahoo.com
authors.forename: Olukayode Adeolu
authors.initials: OA
authors.lastname: Arowolo
authors.forename: Andrew Akinbolaji
authors.initials: AA
authors.lastname: Akinkuolie
authors.forename: Oladejo Olukayode
authors.initials: OO
authors.lastname: Lawal
authors.forename: Olusegun Isaac
authors.initials: OI
authors.lastname: Alatise
authors.forename: Abdulkadir Ayo
authors.initials: AA
authors.lastname: Salako
authors.forename: Adewale Oluseye
authors.initials: AO
authors.lastname: Adisa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009549:Nigeria / Q000453:epidemiology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil
references.citation: Clin Oncol (R Coll Radiol). 1991 Mar;3(2):78-80
references.pmid: 2031886
references.citation: Clin Breast Cancer. 2005 Dec;6(5):391-401
references.pmid: 16381622
references.citation: Ann Oncol. 2001 May;12(5):685-91
references.pmid: 11432629
references.citation: Ann Oncol. 1998 Nov;9(11):1179-84
references.pmid: 9862047
references.citation: Surg Clin North Am. 2007 Apr;87(2):399-415, ix
references.pmid: 17498534
references.citation: J Clin Oncol. 1995 Mar;13(3):547-52
references.pmid: 7884414
references.citation: Rev Prat. 1998 Jan 1;48(1):21-7
references.pmid: 9781206
references.citation: J R Coll Surg Edinb. 1992 Jun;37(3):159-61
references.pmid: 1404038
references.citation: Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15
references.pmid: 16430397
references.citation: Cancer Res. 1979 Oct;39(10):3861-5
references.pmid: 476622
references.citation: CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27
references.pmid: 8548526
references.citation: Hong Kong Med J. 2000 Sep;6(3):265-8
references.pmid: 11025844
references.citation: Ann Surg Oncol. 2008 Jul;15(7):1983-8
references.pmid: 18408976
references.citation: Int J Radiat Oncol Biol Phys. 1992;23(5):949-60
references.pmid: 1639655
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: J Clin Oncol. 1997 Jul;15(7):2483-93
references.pmid: 9215816
references.citation: Cancer. 1994 Jul 1;74(1 Suppl):416-23
references.pmid: 8004615
references.citation: Ann Oncol. 1991 May;2(5):347-54
references.pmid: 1954179
references.citation: Ann Surg Oncol. 2003 Jul;10(6):635-44
references.pmid: 12839848
references.citation: Eur J Cancer. 1997 Jun;33(7):1075-107
references.pmid: 9376190
references.citation: Breast J. 2006 Jan-Feb;12 Suppl 1:S54-69
references.pmid: 16430399
references.citation: Asian J Surg. 2004 Apr;27(2):130-3
references.pmid: 15140665
references.citation: Eur J Cancer. 1994;30A(5):645-52
references.pmid: 8080680
references.citation: Oncol Rep. 2000 Mar-Apr;7(2):277-83
references.pmid: 10671671
references.citation: East Afr Med J. 2000 Oct;77(10):539-43
references.pmid: 12862121
references.citation: Afr J Reprod Health. 2001 Aug;5(2):56-62
references.pmid: 12471913
references.citation: Br J Surg. 1989 Feb;76(2):182-4
references.pmid: 2702455
references.citation: Breast J. 2006 Jan-Feb;12 Suppl 1:S38-53
references.pmid: 16430398
references.citation: West Afr J Med. 2005 Jul-Sep;24(3):209-13
references.pmid: 16276696
references.citation: Eur J Surg Oncol. 2009 Feb;35(2):113-22
references.pmid: 18502088
references.citation: J Clin Oncol. 2006 Apr 20;24(12):1940-9
references.pmid: 16622270
references.citation: Ann Oncol. 1994 Sep;5(7):591-5
references.pmid: 7993833
references.citation: Breast. 2006 Jun;15(3):399-409
references.pmid: 16085418
references.citation: Semin Oncol. 1996 Aug;23(4):464-74
references.pmid: 8757273
references.citation: Cancer. 2008 Oct 15;113(8 Suppl):2315-24
references.pmid: 18837023
references.citation: Oncologist. 2002;7(3):239-45
references.pmid: 12065797
references.citation: Eur J Cancer. 1991;27(12):1668-71
references.pmid: 1782080
references.citation: Eur J Cancer. 1995 Nov;31A(12):1969-75
references.pmid: 8562150
references.citation: Cancer Res. 1983 Apr;43(4):1488-92
references.pmid: 6831397
references.citation: Breast J. 2006 Jan-Feb;12 Suppl 1:S70-80
references.pmid: 16430400
references.citation: Ann Oncol. 1999 Jan;10(1):47-52
references.pmid: 10076721
references.citation: West Afr J Med. 2000 Apr-Jun;19(2):120-5
references.pmid: 11070747
references.citation: West Afr J Med. 2000 Jul-Sep;19(3):179-91
references.pmid: 11126081
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3628-36
references.pmid: 12202663
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1304-10
references.pmid: 11870173